**Supplemental Table 1.** Total number and sample percent positivity for each cohort.

| Samples     | Assay          | Positive (%) | High-Titer (%) |
|-------------|----------------|--------------|----------------|
| **Cohort 1** |                |              |                |
| (N=1005)    | Roche Anti-NC  | 923 (91.8)   | 191 (19.0)     |
|             | Roche Anti-S   | 943 (93.8)   | 453 (45.1)     |
| **Cohort 2** |                |              |                |
| N=594       | Roche Anti-NC  | 536 (90.2)   | 114 (19.2)     |
|             | Roche Anti-S   | 549 (92.4)   | 251 (42.3)     |
|             | Ortho Anti-S   | 555 (93.4)   | 348 (58.6)     |
| **Cohort 3** |                |              |                |
| N=187       | Roche Anti-NC  | 166 (88.8)   | 36 (19.3)      |
|             | Roche Anti-S   | 169 (90.4)   | 91 (48.7)      |
|             | Ortho Anti-S   | 169 (90.4)   | 120 (64.2)     |
|             | Abbott Anti-NC | 157 (84.0)   | 100 (53.5)     |
|             | Genscript cPass nAb | 168 (89.8) | 112 (59.9)     |
**Supplemental Table 2.** Positive percent agreement and high-titer percent agreement between assays for each cohort.

| Cohort 1 | Positive % Agreement |  |  |  |
|-----------|----------------------|---|---|---|
| Roche Anti-NC | 97.7% |  |  |  |

| Cohort 1 | High-Titer % Agreement |  |  |  |
|-----------|-------------------------|---|---|---|
| Roche Anti-NC | 26.5% |  |  |  |

| Cohort 2 | Positive % Agreement | Roche Anti-S | Ortho Anti-S |  |
|-----------|----------------------|-------------|-------------|---|
| Roche Anti-NC | 97.3% | 95.2% |  |  |
| Roche Anti-S | 97.1% |  |  |  |

| Cohort 2 | High-Titer % Agreement | Roche Anti-S | Ortho Anti-S |  |
|-----------|-------------------------|-------------|-------------|---|
| Roche Anti-NC | 26.3% | 24.9% |  |  |
| Roche Anti-S | 66.4% |  |  |  |

| Cohort 3 | Positive % Agreement | Roche Anti-S | Ortho Anti-S | Abbott Anti-NC | Genscript cPass nAb |
|-----------|----------------------|-------------|-------------|---------------|------------------|
| Roche Anti-NC | 98.2% | 98.2% | 94.6% | 96.5% |  |
| Roche Anti-S | 98.8% | 92.9% | 95.9% |  |  |
| Ortho Anti-S | 92.9% | 95.9% |  |  |  |
| Abbott Anti-NC |  |  |  |  |  |

| Cohort 3 | High-Titer % Agreement | Roche Anti-S | Ortho Anti-S | Abbott Anti-NC | Genscript cPass nAb |
|-----------|-------------------------|-------------|-------------|---------------|------------------|
|  |  |  |  |  |  |  |
| Test          | Value 1 | Value 2 | Value 3 | Value 4 |
|--------------|---------|---------|---------|---------|
| Roche Anti-NC| 28.3%   | 26.8%   | 28.3%   | 26.5%   |
| Roche Anti-S | 71.5%   | 61.9%   | 66.4%   |         |
| Ortho Anti-S |         | 73.2%   | 82.7%   |         |
| Abbott Anti-NC|        |         |         | 75.2%   |
# Supplemental Table 3. ROC data and new calculated high-titer cutoffs

| N  | Gold Standard | Test          | AUC  | Std. Error | 95% CI       | P value (PPA+NPA-1) | Max [PPA-NPA] | Min √((1-PPA)^2 + (1-NPA)^2) |
|----|---------------|---------------|------|------------|--------------|---------------------|---------------|--------------------------------|
| 1005 (Cohort 1) | Roche Anti-NC | Roche Anti-S  | 0.7034 | 0.01842    | 0.6673 to 0.7396 | <0.001             | 88            | 159                             |
|     | Roche Anti-S  | Roche Anti-NC | 0.7937 | 0.01414    | 0.7660 to 0.8215 | <0.0001            | 53            | 65                              |
| 594 (Cohort 2)  | Roche Anti-NC | Roche Anti-S  | 0.7105 | 0.02374    | 0.6639 to 0.7570 | <0.001             | 68            | 136                             |
|     | Ortho Anti-S  | Roche Anti-NC | 0.6758 | 0.02521    | 0.6264 to 0.7252 | <0.001             | 10            | 12.5                            |
|     | Roche Anti-S  | Ortho Anti-S  | 0.8018 | 0.01806    | 0.7664 to 0.8372 | <0.001             | 52            | 69                              |
|     | Ortho Anti-S  | Roche Anti-NC | 0.9478 | 0.007926   | 0.9322 to 0.9633 | <0.001             | 13.6          | 12.2                            |
|     | Ortho Anti-S  | Roche Anti-NC | 0.7912 | 0.02019    | 0.7517 to 0.8308 | <0.001             | 32            | 54                              |
|     | Roche Anti-S  | Roche Anti-NC | 0.9299 | 0.009811   | 0.9107 to 0.9491 | <0.001             | 92            | 84                              |
| 187 (Cohort 3)  | Roche Anti-NC | Roche Anti-S  | 0.7182 | 0.03926    | 0.6412 to 0.7951 | <0.001             | 68            | 161                             |
|     | Ortho Anti-S  | Roche Anti-NC | 0.6756 | 0.04215    | 0.3930 to 0.7582 | 0.001             | 10.8          | 13.4                            |
|     | Abbott Anti-NC| Roche Anti-NC | 0.6718 | 0.03778    | 0.5978 to 0.7459 | 0.001             | 4.5           | 5.9                             |
|     | Genscript cPass nAb | Roche Anti-S  | 0.6878 | 0.04346    | 0.6026 to 0.7730 | <0.001             | 67            | 77                              |
|     | Roche Anti-S  | Roche Anti-NC | 0.8374 | 0.03038    | 0.7778 to 0.8969 | <0.001             | 69            | 75                              |

Youden's index: \( \sqrt{(1 - PPA)^2 + (1 - NPA)^2} \)
|                                | Ortho Anti-S | Abbott Anti-NC | Genscript cPass nAb | Ortho Anti-S | Roche Anti-NC | Abbott Anti-NC | Genscript cPass nAb | Roche Anti-NC | Abbott Anti-NC | Genscript cPass nAb | Roche Anti-NC | Abbott Anti-NC | Genscript cPass nAb |
|--------------------------------|--------------|---------------|--------------------|--------------|---------------|---------------|--------------------|---------------|---------------|--------------------|---------------|---------------|--------------------|
|                                | O.9211       | 0.01812       | 0.8856 to 0.9566   | <0.001       | 11.3          | 12.4          | 11.3               |               |               |                   |               |               |                    |
|                                | 0.8471       | 0.0282        | 0.7919 to 0.9024   | <0.001       | 3.5           | 5             | 4.5                |               |               |                   |               |               |                    |
|                                | 0.922        | 0.01806       | 0.8866 to 0.9574   | <0.001       | 77            | 75            | 75                 |               |               |                   |               |               |                    |
|                                | Ortho Anti-S | Roche Anti-NC |                    |              |               |               |                    |               |               |                   |               |               |                    |
|                                | 0.8841       | 0.02841       | 0.8284 to 0.9398   | <0.001       | 53            | 57            | 56                 |               |               |                   |               |               |                    |
|                                | 0.9491       | 0.01567       | 0.9184 to 0.9798   | <0.001       | 108           | 99            | 97                 |               |               |                   |               |               |                    |
|                                | 0.9333       | 0.01842       | 0.8972 to 0.9694   | <0.001       | 3.5           | 4.1           | 3.5                |               |               |                   |               |               |                    |
|                                | 0.9527       | 0.01602       | 0.9213 to 0.9841   | <0.001       | 67            | 67            | 67                 |               |               |                   |               |               |                    |
|                                | Abbott Anti-NC | Roche Anti-NC |                    |              |               |               |                    |               |               |                   |               |               |                    |
|                                | 0.8562       | 0.03005       | 0.7973 to 0.9151   | <0.001       | 53            | 70            | 69                 |               |               |                   |               |               |                    |
|                                | 0.8753       | 0.02459       | 0.8272 to 0.9235   | <0.001       | 108           | 126           | 115                |               |               |                   |               |               |                    |
|                                | 0.9094       | 0.02083       | 0.8685 to 0.9502   | <0.001       | 12.2          | 11.5          | 12.2               |               |               |                   |               |               |                    |
|                                | 0.9243       | 0.01874       | 0.8876 to 0.9610   | <0.001       | 70            | 73            | 70                 |               |               |                   |               |               |                    |
|                                | Genscript cPass nAb | Roche Anti-NC |                    |              |               |               |                    |               |               |                   |               |               |                    |
|                                | 0.8208       | 0.03403       | 0.7541 to 0.8875   | <0.001       | 53            | 65            | 58                 |               |               |                   |               |               |                    |
|                                | 0.9207       | 0.01846       | 0.8845 to 0.9568   | <0.001       | 108           | 112           | 108                |               |               |                   |               |               |                    |
|                                | 0.9594       | 0.01325       | 0.9334 to 0.9854   | <0.001       | 10.5          | 10.8          | 10.5               |               |               |                   |               |               |                    |
|                                | Abbott Anti-NC | Roche Anti-NC |                    |              |               |               |                    |               |               |                   |               |               |                    |
|                                | 0.9164       | 0.02074       | 0.8758 to 0.9571   | <0.001       | 4.9           | 4.4           | 4.5                |               |               |                   |               |               |                    |
Supplemental Table 4. Calculated difference between FDA EUA high-titer cutoff value and differences between calculated values from Supplemental Table 3.

| N       | Gold Standard | Test          | EUA Value | Minimum Difference | Maximum Difference | Minimum Absolute Difference (%) |
|---------|---------------|---------------|-----------|--------------------|--------------------|---------------------------------|
| 1005 (Cohort 1) |                | Roche Anti-NC | Roche Anti-S | 132                | -27                | 44                              | 17 (13)                         |
|         |                | Roche Anti-S  | Roche Anti-NC | 109                | 44                 | 56                              | 44 (40)                         |
| 594 (Cohort 2) | Roche Anti-NC | Roche Anti-S  | 132        | -4                 | 64                 | 4                               | 3 (1)                           |
|         | Ortho Anti-S   | 9.5           | -3         | -0.5               | 0.5                | 0.5 (5)                         |
|         | Roche Anti-NC  | 109           | 40         | 57                 | 40 (37)            |
|         | Ortho Anti-S   | 9.5           | -4.1       | -2.7               | 2.7 (28)           |
| Ortho Anti-S | Roche Anti-NC | 109           | 55         | 77                 | 55 (50)            |
|         | Roche Anti-S  | 132           | 40         | 48                 | 40 (30)            |
| 187 (Cohort 3) | Roche Anti-NC | Roche Anti-S  | 132        | -29                | 64                 | 23 (17)                         |
|         | Ortho Anti-S   | 9.5           | -3.9       | -1.3               | 1.3 (14)           |
|         | Abbott Anti-NC | 4.5           | -1.5       | 0                  | 0 (0)              |
|         | Genscript cPass nAb | 68        | -9         | 1                  | 1 (1)              |
|         | Roche Anti-NC  | 109           | 34         | 40                 | 34 (31)            |
|         | Ortho Anti-S   | 9.5           | -2.9       | -1.8               | 1.8 (19)           |
|         | Abbott Anti-NC | 4.5           | -0.5       | 1                  | 0 (0)              |
|         | Genscript cPass nAb | 68        | -9         | -7                 | 7 (10)             |
| Ortho Anti-S | Roche Anti-NC | 109           | 52         | 56                 | 52 (48)            |
|         | Roche Anti-S  | 132           | 24         | 35                 | 24 (18)            |
|         | Abbott Anti-NC | 4.5           | 0.4        | 1                  | 0.4 (9)            |
|         | Genscript cPass nAb | 68        | 1          | 1                  | 1 (1)              |
| Abbott Anti-NC | Roche Anti-NC | 109           | 39         | 56                 | 39 (36)            |
|         | Roche Anti-S  | 132           | 6          | 24                 | 6 (5)              |
|         | Ortho Anti-S  | 9.5           | -2.7       | -2                 | 2 (21)             |
|                   | Genscript cPass nAb | Roche Anti-NC | Roche Anti-S | Ortho Anti-S | Abbott Anti-NC |
|-------------------|---------------------|---------------|--------------|--------------|----------------|
| Genscript cPass nAb | 68                  | 109           | 132          | 9.5          | 4.5            |
|                   | -5                  | 44            | 20           | -1.3         | -0.4           |
|                   | -2                  | 56            | 24           | -1           | 0.1            |
|                   | 2 (3)               | 44 (40)       | 20 (15)      | 1 (11)       | 0 (0)          |
**Supplemental Table 5.** Cohort 2 statistics by age category

**Summary of 594 samples tested across three assays**

By age category

|                     | 1) <40 (N=237) | 2) 40 to <55 (N=147) | 3) >=55 (N=210) | Total (N=594) | p value |
|---------------------|----------------|-----------------------|-----------------|---------------|---------|
| **Sex**             |                |                       |                 |               | 0.0169  |
| F                   | 129 (54.4%)    | 69 (46.9%)            | 86 (41.0%)      | 284 (47.8%)   |         |
| M                   | 108 (45.6%)    | 78 (53.1%)            | 124 (59.0%)     | 310 (52.2%)   |         |
| **Ortho [VITROS Anti-SARS-CoV-2 IgG]** |                |                       |                 |               | 0.0001  |
| Median              | 9.9            | 12.4                  | 12.5            | 11.1          |         |
| Q1, Q3              | 4.8, 14.0      | 4.8, 18.2             | 6.0, 18.7       | 5.3, 17.0     |         |
| Range               | (0.0-28.9)     | (0.0-28.4)            | (0.0-29.5)      | (0.0-29.5)    |         |
| **Ortho [VITROS Anti-SARS-CoV-2 IgG]: High titer** |                |                       |                 |               | 0.0875  |
| 0) S/C<9.5          | 111 (46.8%)    | 57 (38.8%)            | 78 (37.1%)      | 246 (41.4%)   |         |
| 1) S/C>=9.5         | 126 (53.2%)    | 90 (61.2%)            | 132 (62.9%)     | 348 (58.6%)   |         |
| **Roche COI [Elecsys Anti-SARS-CoV-2]** |                |                       |                 |               | 0.0532  |
| Median              | 52.9           | 65.4                  | 71.0            | 61.1          |         |
| Q1, Q3              | 9.8, 97.0      | 16.9, 99.7            | 23.1, 103.0     | 16.9, 99.9    |         |
| Range               | (0.1-160.0)    | (0.1-167.0)           | (0.1-152.0)     | (0.1-167.0)   |         |
| **Roche COI [Elecsys Anti-SARS-CoV-2]: High titer** |                |                       |                 |               | 0.3914  |
| 0) COI<109          | 191 (80.6%)    | 124 (84.4%)           | 165 (78.6%)     | 480 (80.8%)   |         |
| 1) COI>=109         | 46 (19.4%)     | 23 (15.6%)            | 45 (21.4%)      | 114 (19.2%)   |         |
| **Roche U/mL [Elecsys Anti-SARS-CoV-2 S]** |                |                       |                 |               | 0.0003  |
| Median              | 84.6           | 104.0                 | 143.5           | 102.5         |         |
| Q1, Q3              | 22.7, 168.0    | 30.6, 277.6           | 40.0, 295.2     | 32.4, 238.4   |         |
| Range               | (0.4-2230.0)   | (0.4-2501.0)          | (0.4-2501.0)    | (0.4-2501.0)  |         |
| **Roche U/mL [Elecsys Anti-SARS-CoV-2 S]: High titer** |                |                       |                 |               | 0.0008  |
| 0) <132 U/mL        | 157 (66.2%)    | 84 (57.1%)            | 102 (48.6%)     | 343 (57.7%)   |         |
| 1) >=132 U/mL       | 80 (33.8%)     | 63 (42.9%)            | 108 (51.4%)     | 251 (42.3%)   |         |

(report generated on 26APR2021)

1Chi-Square  2Kruskal Wallis
### Supplemental Table 6. Cohort 2 statistics by sex

**Summary of 594 samples tested across three assays**

**By sex**

|                  | F (N=284) | M (N=310) | Total (N=594) | p value |
|------------------|-----------|-----------|---------------|---------|
| **Age**          |           |           |               |         |
| Median           | 42.5      | 49.2      | 47.8          | 0.0059^1|
| Q1, Q3           | 28.2, 57.8| 32.4, 59.4| 31.0, 59.0    |         |
| Range            | (16.3-73.1)| (17.2-81.2)| (16.3-81.2)   |         |
| **Age (category)**|          |           |               |         |
| 1) <40           |           |           |               |         |
| 2) 40 to <55     |           |           |               |         |
| 3) >=55          |           |           |               |         |
| **Ortho [VITROS Anti-SARS-CoV-2 IgG]** | | | | 0.5599^1 |
| Median           | 11.1      | 11.1      | 11.1          |         |
| Q1, Q3           | 5.3, 15.8 | 5.3, 17.7 | 5.3, 17.0    |         |
| Range            | (0.0-29.5)| (0.0-28.2)| (0.0-29.5)   |         |
| **Ortho [VITROS Anti-SARS-CoV-2 IgG]: High titer** | | | | 0.5465^2 |
| 0) S/C<9.5       | 114 (40.1%)| 132 (42.6%)| 246 (41.4%)  |         |
| 1) S/C>=9.5      | 170 (59.9%)| 178 (57.4%)| 348 (58.6%)  |         |
| **Roche COI [Elecsys Anti-SARS-CoV-2]** | | | | 0.9477^1 |
| Median           | 61.7      | 60.3      | 61.1          |         |
| Q1, Q3           | 16.2, 101.0| 17.1, 99.3| 16.9, 99.9   |         |
| Range            | (0.1-160.0)| (0.1-167.0)| (0.1-167.0)  |         |
| **Roche COI [Elecsys Anti-SARS-CoV-2]: High titer** | | | | 0.4660^2 |
| 0) COI<109       | 226 (79.6%)| 254 (81.9%)| 480 (80.8%)  |         |
| 1) COI>=109      | 58 (20.4%) | 56 (18.1%) | 114 (19.2%)  |         |
| **Roche U/mL [Elecsys Anti-SARS-CoV-2 S]** | | | | 0.3605^1 |
| Median           | 90.8      | 108.5     | 102.5         |         |
| Q1, Q3           | 28.5, 224.8| 34.9, 256.8| 32.4, 238.4 |         |
| Range            | (0.4-2501.0)| (0.4-2501.0)| (0.4-2501.0)|         |
| **Roche U/mL [Elecsys Anti-SARS-CoV-2 S]: High titer** | | | | 0.4051^2 |
| 0) <132 U/mL     | 169 (59.5%)| 174 (56.1%)| 343 (57.7%)  |         |
| 1) >=132 U/mL    | 115 (40.5%)| 136 (43.9%)| 251 (42.3%)  |         |

(report generated on 26APR2021)

^1 Wilcoxon  ^2 Chi-Square
### Supplemental Table 7. Cohort 3 statistics by age category

**Summary of 187 samples tested across six assays**

**By age category**

| Assay                          | 1) <40 (N=69) | 2) 40 to <55 (N=48) | 3) ≥55 (N=70) | Total (N=187) | p value |
|-------------------------------|---------------|---------------------|---------------|---------------|---------|
| **Sex**                       |               |                     |               |               | 0.04741 |
| F                             | 37 (53.6%)    | 29 (60.4%)          | 27 (38.6%)    | 93 (49.7%)    |         |
| M                             | 32 (46.4%)    | 19 (39.6%)          | 43 (61.4%)    | 94 (50.3%)    |         |
| **Ortho [VITROS Anti-SARS-CoV-2 IgG]** |               |                     |               |               | 0.01902 |
| Median                        |               | 10.0                | 13.7          | 12.4          | 12.2    |
| Q1, Q3                        | 3.0, 14.4     | 4.8, 17.7           | 7.8, 17.0     | 6.6, 16.5     |         |
| Range                         | (0.0-22.4)    | (0.0-27.1)          | (0.0-25.1)    | (0.0-27.1)    |         |
| **Ortho [VITROS Anti-SARS-CoV-2 IgG]: High titer** |               |                     |               |               | 0.39201 |
| 0) S/C<9.5                    | 29 (42.0%)    | 16 (33.3%)          | 22 (31.4%)    | 67 (35.8%)    |         |
| 1) S/C≥9.5                    | 40 (58.0%)    | 32 (66.7%)          | 48 (68.6%)    | 120 (64.2%)   |         |
| **Roche COI [Elecsys Anti-SARS-CoV-2]** |               |                     |               |               | 0.02082 |
| Median                        | 55.8          | 70.9                | 87.4          | 72.6          |         |
| Q1, Q3                        | 13.4, 92.2    | 19.0, 99.8          | 43.1, 111.0   | 25.5, 101.0   |         |
| Range                         | (0.1-152.0)   | (0.1-138.0)         | (0.1-152.0)   | (0.1-152.0)   |         |
| **Roche COI [Elecsys Anti-SARS-CoV-2]: High titer** |               |                     |               |               | 0.17891 |
| 0) COI<109                    | 57 (82.6%)    | 42 (87.5%)          | 52 (74.3%)    | 151 (80.7%)   |         |
| 1) COI≥109                    | 12 (17.4%)    | 6 (12.5%)           | 18 (25.7%)    | 36 (19.3%)    |         |
| **Roche U/mL [Elecsys Anti-SARS-CoV-2 S]** |               |                     |               |               | 0.03532 |
| Median                        | 108.0         | 126.0               | 166.5         | 127.0         |         |
| Q1, Q3                        | 38.7, 157.0   | 32.5, 297.2         | 60.0, 231.0   | 45.1, 229.0   |         |
| Range                         | (0.4-683.2)   | (0.4-2501.0)        | (0.4-2430.0)  | (0.4-2501.0)  |         |
| **Roche U/mL [Elecsys Anti-SARS-CoV-2 S]: High titer** |               |                     |               |               | 0.04361 |
| 0) <132 U/mL                  | 42 (60.9%)    | 26 (54.2%)          | 28 (40.0%)    | 96 (51.3%)    |         |
| 1) ≥132 U/mL                  | 27 (39.1%)    | 22 (45.8%)          | 42 (60.0%)    | 91 (48.7%)    |         |
| **Abbott [SARS-CoV-2 IgG]**   |               |                     |               |               | 0.13392 |
| Median                        | 4.3           | 5.0                 | 5.5           | 4.9           |         |
| Q1, Q3                        | 1.7, 6.5      | 2.1, 6.7            | 3.2, 7.0      | 2.5, 6.7      |         |
| Range                         | (0.0-8.5)     | (0.0-8.2)           | (0.0-7.9)     | (0.0-8.5)     |         |
| **Abbott [SARS-CoV-2 IgG]: High titer** |               |                     |               |               | 0.45001 |
| 0) Index (S/C)<4.5            | 37 (53.6%)    | 21 (43.8%)          | 31 (44.3%)    | 89 (47.6%)    |         |
| 1) Index (S/C)≥4.5            | 32 (46.4%)    | 27 (56.3%)          | 39 (55.7%)    | 98 (52.4%)    |         |
| **GenScript cPass SARS-CoV-2 Neutralization Antibody** |               |                     |               |               | 0.01002 |


| Age Category | Median | 1) <40 (N=69) | 2) 40 to <55 (N=48) | 3) >=55 (N=70) | Total (N=187) | p value |
|--------------|--------|---------------|-----------------------|----------------|----------------|---------|
| Median       | 66.8   | 77.4          | 78.4                  | 74.0           |                |         |
| Q1, Q3       | 43.6, 79.1 | 47.5, 87.8 | 60.9, 89.2           | 51.0, 85.3    |                |         |
| Range        | (12.9-96.3) | (4.2-98.0) | (9.4-97.6)           | (4.2-98.0)     |                |         |

GenScript [cPass SARS-CoV-2 Neutralization](report generated on 26APR2021)  
0.0575<sup>1</sup>  
**Antibody [High titer]**  
0) Inhibition<68%  
1) Inhibition>=68%  
|                | 1) <40 (N=69) | 2) 40 to <55 (N=48) | 3) >=55 (N=70) | Total (N=187) | p value |
|----------------|---------------|----------------------|----------------|----------------|---------|
| 0) Inhibition<68% | 36 (52.2%)  | 18 (37.5%)           | 23 (32.9%)     | 77 (41.2%)     |         |
| 1) Inhibition>=68%| 33 (47.8%)  | 30 (62.5%)           | 47 (67.1%)     | 110 (58.8%)    |         |

<sup>1</sup>Chi-Square  <sup>2</sup>Kruskal Wallis
### Supplemental Table 8. Cohort 3 statistics by sex

#### Summary of 187 samples tested across six assays

|                  | F (N=93) | M (N=94) | Total (N=187) | p value |
|------------------|----------|----------|---------------|---------|
| **Age**          |          |          |               | 0.10681 |
| Median           | 48.0     | 53.0     | 50.0          |         |
| Q1, Q3           | 33.0, 56.0 | 34.0, 60.0 | 34.0, 59.0 |         |
| Range            | (20.0-70.0) | (21.0-75.0) | (20.0-75.0) |         |
| **Age (category)** |          |          |               | 0.04742 |
| 1) <40           |          |          |               |         |
| 2) 40 to <55     |          |          |               |         |
| 3) >=55          |          |          |               |         |
| **Ortho [VITROS Anti-SARS-CoV-2 IgG]** |          |          |               | 0.80571 |
| Median           | 11.9     | 12.3     | 12.2          |         |
| Q1, Q3           | 6.9, 15.1 | 6.2, 16.7 | 6.6, 16.5 |         |
| Range            | (0.0-27.1) | (0.0-25.1) | (0.0-27.1) |         |
| **Ortho [VITROS Anti-SARS-CoV-2 IgG]: High titer** |          |          |               | 0.83592 |
| 0) S/C<9.5       |          |          |               |         |
| 1) S/C>=9.5      |          |          |               |         |
| **Roche COI [Elecsys Anti-SARS-CoV-2]** |          |          |               | 0.41141 |
| Median           | 71.1     | 79.2     | 72.6          |         |
| Q1, Q3           | 20.0, 99.9 | 35.0, 102.0 | 25.5, 101.0 |         |
| Range            | (0.1-137.0) | (0.1-152.0) | (0.1-152.0) |         |
| **Roche COI [Elecsys Anti-SARS-CoV-2]: High titer** |          |          |               | 0.73742 |
| 0) COI<109       |          |          |               |         |
| 1) COI>=109      |          |          |               |         |
| **Roche U/mL [Elecsys Anti-SARS-CoV-2 S]** |          |          |               | 0.88291 |
| Median           | 126.0    | 130.5    | 127.0         |         |
| Q1, Q3           | 45.4, 224.0 | 40.5, 252.8 | 45.1, 229.0 |         |
| Range            | (0.4-2501.0) | (0.4-2430.0) | (0.4-2501.0) |         |
| **Roche U/mL [Elecsys Anti-SARS-CoV-2 S]: High titer** |          |          |               | 0.71312 |
| 0) <132 U/mL     |          |          |               |         |
| 1) >=132 U/mL    |          |          |               |         |
| **Abbott [SARS-CoV-2 IgG]** |          |          |               | 0.26731 |
| Median           | 4.5      | 5.5      | 4.9           |         |
| Q1, Q3           | 2.3, 6.5 | 2.7, 6.9 | 2.5, 6.7     |         |
| Range            | (0.0-8.5) | (0.0-8.2) | (0.0-8.5) |         |
Summary of 187 samples tested across six assays
By sex

|                | F (N=93) | M (N=94) | Total (N=187) | p value |
|----------------|----------|----------|---------------|---------|
| **Abbott [SARS-CoV-2 IgG]: High titer** |           |          |               |         |
| 0) Index (S/C)<4.5 | 47 (50.5%) | 42 (44.7%) | 89 (47.6%) | 0.4227  |
| 1) Index (S/C)>=4.5 | 46 (49.5%) | 52 (55.3%) | 98 (52.4%) |         |

**GenScript [cPass SARS-CoV-2 Neutralization Antibody]**

|                |          |          |               |         |
|----------------|----------|----------|---------------|---------|
| Median         | 74.9     | 72.6     | 74.0          |         |
| Q1, Q3         | 50.5, 85.9 | 51.5, 84.4 | 51.0, 85.3 |         |
| Range          | (9.4-98.0) | (4.2-97.6) | (4.2-98.0) |         |

**GenScript [cPass SARS-CoV-2 Neutralization Antibody]: High titer**

|                |          |          |               |         |
|----------------|----------|----------|---------------|---------|
| 0) Inhibition<68% | 37 (39.8%) | 40 (42.6%) | 77 (41.2%) |         |
| 1) Inhibition>=68% | 56 (60.2%) | 54 (57.4%) | 110 (58.8%) |         |

(report generated on 26APR2021)

Wilcoxon  Chi-Square